Raymond James & Associates Has $2.61 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Raymond James & Associates trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 70,664 shares of the biopharmaceutical company’s stock after selling 6,657 shares during the quarter. Raymond James & Associates’ holdings in Halozyme Therapeutics were worth $2,612,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Hsbc Holdings PLC boosted its stake in shares of Halozyme Therapeutics by 35.0% during the third quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company’s stock valued at $3,006,000 after purchasing an additional 20,346 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Halozyme Therapeutics by 174.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after purchasing an additional 563,989 shares in the last quarter. Aurora Investment Counsel acquired a new stake in shares of Halozyme Therapeutics during the third quarter valued at about $1,347,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter valued at about $591,000. Finally, Boston Partners acquired a new stake in shares of Halozyme Therapeutics during the third quarter valued at about $3,186,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on HALO shares. The Goldman Sachs Group cut their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. TD Cowen initiated coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective on the stock. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. Finally, HC Wainwright lifted their price objective on Halozyme Therapeutics from $48.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.29.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total transaction of $395,500.00. Following the completion of the sale, the senior vice president now owns 156,558 shares in the company, valued at $6,191,868.90. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $38.72 on Tuesday. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The business’s 50 day moving average price is $39.32 and its two-hundred day moving average price is $37.76. The firm has a market cap of $4.92 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 0.46 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.33 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.